专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08338411B2 Compounds 有权
标题翻译：化合物
公开(公告)号：US08338411B2
公开(公告)日：2012-12-25
申请号：US12631139
申请日：2009-12-04
申请人： Edit Susan , Kinga Boer , Zoltan Kapui , Geza Timari , Sandor Batori , Zoltan Szlavik , Endre Mikus , Judit Vargane Szeredi , Michel Finet , Katalin Urban Szabo , Tibor Szabo
发明人： Edit Susan , Kinga Boer , Zoltan Kapui , Geza Timari , Sandor Batori , Zoltan Szlavik , Endre Mikus , Judit Vargane Szeredi , Michel Finet , Katalin Urban Szabo , Tibor Szabo
IPC分类号： A61K31/535 , C07D215/38
CPC分类号： C07D471/04
摘要： The present invention relates to the adenosine A3 receptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.
摘要翻译：本发明涉及含有通式（I）的化合物的药物组合物，其通式（I）的腺苷A 3受体配体，其有利于拮抗剂，其盐，溶剂合物，N-氧化物和异构体，），它们的盐，溶剂合物，N-氧化物和异构体，通式（I）的化合物，其盐，溶剂合物，N-氧化物和异构体用于制备通式（I ），它们的盐，溶剂合物，N-氧化物和异构体，以及通式（II），（VI），（XI），（XII）和（XV）的新中间体及其制备。

2. 发明授权

US08071601B2 Aminoquinoline derivatives and their use as adenosine A3 ligands 失效
标题翻译：氨基喹啉衍生物及其作为腺苷A3配体的用途
公开(公告)号：US08071601B2
公开(公告)日：2011-12-06
申请号：US13008398
申请日：2011-01-18
申请人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
发明人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
IPC分类号： A61K31/497 , A61K31/47 , C07D401/04 , C07D453/04
CPC分类号： C07D405/12 , C07C229/50 , C07D215/48 , C07D405/14 , C07D409/12 , C07D409/14 , C07D491/04
摘要： The present invention relates to an adenosine A3 receptor ligand of the general formula (I).
摘要翻译：本发明涉及通式（I）的腺苷A3受体配体。

3. 发明授权

US08063045B2 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity 失效
标题翻译：具有二肽基肽酶抑制活性的氟代吡咯烷
公开(公告)号：US08063045B2
公开(公告)日：2011-11-22
申请号：US12697762
申请日：2010-02-01
申请人： Peter Aranyi , Laszlo Balazs , Imre Bata , Sandor Batori , Eva Boronkay , Philippe Bovy , Karoly Kanai , Zoltan Kapui , Edit Susan , Tibor Szabo , Lajos T. Nagy , Katalin Urban-Szabo , Marton Varga
发明人： Peter Aranyi , Laszlo Balazs , Imre Bata , Sandor Batori , Eva Boronkay , Philippe Bovy , Karoly Kanai , Zoltan Kapui , Edit Susan , Tibor Szabo , Lajos T. Nagy , Katalin Urban-Szabo , Marton Varga
IPC分类号： A61K31/53 , A61K31/50 , A61K31/435 , A61K31/44 , A61K31/428 , A61K31/423 , A61K31/4184 , C07D241/00 , C07D401/14 , C07D211/00 , C07D207/00
CPC分类号： C07D451/04 , C07D207/16 , C07D211/58 , C07D401/04 , C07D401/14 , C07D405/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D451/14
摘要： The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.
摘要翻译：本发明涉及含有氟原子的新的具有通式（I）的DPP-IV酶抑制剂。

4. 发明授权

US07652021B2 Compounds useful for DPP-IV enzyme inhibition 失效
标题翻译：可用于DPP-IV酶抑制的化合物
公开(公告)号：US07652021B2
公开(公告)日：2010-01-26
申请号：US11364154
申请日：2006-02-28
申请人： Peter Aranyi , Imre Bata , Sandor Batori , Eva Boronkay , Philippe Bovy , Zoltan Kapui , Edit Susan , Tibor Szabo , Katalin Urban-Szabo , Marton Varga
发明人： Peter Aranyi , Imre Bata , Sandor Batori , Eva Boronkay , Philippe Bovy , Zoltan Kapui , Edit Susan , Tibor Szabo , Katalin Urban-Szabo , Marton Varga
IPC分类号： C07D403/12 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , A61K31/506 , A61K31/33 , A61K31/41 , A61P3/10
CPC分类号： C04B35/632 , C07D207/16 , C07D213/74 , C07D215/38 , C07D221/22 , C07D231/38 , C07D241/20 , C07D253/06 , C07D261/14 , C07D277/42 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D451/02 , C07D471/04
摘要： The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).
摘要翻译：本发明涉及具有二肽基肽酶IV酶抑制活性的通式（I）的新型化合物，其药物组合物，使用所述化合物的方法，其制备方法和通式（II），（IV）的中间体），（V），（VII），（VIII）和（IX）。

5. 发明申请

US20080280963A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands 审中-公开
公开(公告)号：US20080280963A1
公开(公告)日：2008-11-13
申请号：US12050965
申请日：2008-03-19
申请人： Agnes PAPPNE BEHR , Zoltan KAPUI , Peter ARANYI , Sandor BATORI , Veronika BARTANE BODOR , Lajos T. NAGY , Mihalyne Santa , Marton VARGA , Endre MIKUS , Katalin URBAN-SZABO , Judit VARGANE SZEREDI , Tibor SZABO , Edit SUSAN , Marianna KOVACS
发明人： Agnes PAPPNE BEHR , Zoltan KAPUI , Peter ARANYI , Sandor BATORI , Veronika BARTANE BODOR , Lajos T. NAGY , Mihalyne Santa , Marton VARGA , Endre MIKUS , Katalin URBAN-SZABO , Judit VARGANE SZEREDI , Tibor SZABO , Edit SUSAN , Marianna KOVACS
IPC分类号： A61K31/423 , C07C211/63 , C07D263/54 , A61P31/18 , C07D235/04 , A61K31/14
CPC分类号： C07C233/78 , C07C233/40 , C07D235/28 , C07D263/58
摘要： The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound.The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.

6. 发明申请

US20070021459A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS 有权
标题翻译：吡唑衍生物及其作为OREXIN受体拮抗剂的用途
公开(公告)号：US20070021459A1
公开(公告)日：2007-01-25
申请号：US11425583
申请日：2006-06-21
申请人： Michel ALETRU , Peter ARANYI , Maria BALOGH , Sandor BATORI , Judit BENCE , Philippe BOVY , Zoltan KAPUI , Endre MIKUS , Claudie NAMANE , Christophe PHILIPPO , Tibor SZABO , Zsuzsanna TOMOSKOZI , Katalin URBAN-SZABO
发明人： Michel ALETRU , Peter ARANYI , Maria BALOGH , Sandor BATORI , Judit BENCE , Philippe BOVY , Zoltan KAPUI , Endre MIKUS , Claudie NAMANE , Christophe PHILIPPO , Tibor SZABO , Zsuzsanna TOMOSKOZI , Katalin URBAN-SZABO
IPC分类号： A61K31/4709 , A61K31/4439 , A61K31/415 , C07D403/14 , C07D403/02 , C07D231/14
CPC分类号： C07D409/04 , C07D231/16 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.
摘要翻译：本发明涉及食欲素受体拮抗剂通式（I）化合物及其异构体，盐和溶剂合物，其含有它们的药物组合物及其治疗应用。

7. 发明申请

US20050130981A1 Compounds 失效
标题翻译：化合物
公开(公告)号：US20050130981A1
公开(公告)日：2005-06-16
申请号：US10507005
申请日：2003-03-04
申请人： Peter Aranyl , Laszlo Balazs , Imre Bata , Sandor Batori , Eva Boronkay , Philippe Bovy , Karoly Kanai , Zoltan Kapui , Edit Susan , Tibor Szabo , Lajos Nagy , Katalin Urban-Szabo , Marton Varga
发明人： Peter Aranyl , Laszlo Balazs , Imre Bata , Sandor Batori , Eva Boronkay , Philippe Bovy , Karoly Kanai , Zoltan Kapui , Edit Susan , Tibor Szabo , Lajos Nagy , Katalin Urban-Szabo , Marton Varga
IPC分类号： A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K31/497 , A61K31/501 , A61P1/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/12 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P29/00 , A61P31/18 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D207/16 , C07D211/58 , C07D401/04 , C07D401/14 , C07D405/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D451/04 , C07D451/14 , C07D43/14 , A61K31/506
CPC分类号： C07D451/04 , C07D207/16 , C07D211/58 , C07D401/04 , C07D401/14 , C07D405/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D451/14
摘要： The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.
摘要翻译：本发明涉及含有氟原子的新的具有通式（I）的DPP-IV酶抑制剂。

8. 发明授权

US4697013A Condensed as-triazine derivatives 失效
标题翻译：浓缩的三嗪衍生物
公开(公告)号：US4697013A
公开(公告)日：1987-09-29
申请号：US652613
申请日：1984-09-20
申请人： Andras Messmer , Sandor Batori , Gyorgy Hajos , Pal Benko , Laszlo Pallos , Lujza Petocz , Grasser Katalin , Ibolya Kosoczky
发明人： Andras Messmer , Sandor Batori , Gyorgy Hajos , Pal Benko , Laszlo Pallos , Lujza Petocz , Grasser Katalin , Ibolya Kosoczky
IPC分类号： C07D253/08 , C07D471/04
CPC分类号： C07D471/04
摘要： A one step process for the preparation of compounds having antidepressant activity of the formula I ##STR1## and isomers thereof, wherein R.sub.1, R.sub.2, Z and A.sup.- have the meanings indicated in the claims, which process comprises: heating a compound of the formula II ##STR2## wherein Z, A.sup.-, R.sub.1 and R.sub.2 have the meanings set out in the claims and R.sub.3 stands for hydrogen or C.sub.1-4 alkyl, in the presence of a dehydrating agent to split off a compound of the formula R.sub.3 OH. The invention is also directed to compounds of the formula I, wherein R.sub.2 is halogen and to compositions containing a compound of the formula I which exhibit antidepressant activity.
摘要翻译：制备具有式I的抗抑郁活性的化合物及其异构体的一步法，其中R1，R2，Z和A具有权利要求中所示的含义，该方法包括：将式II其中Z，A，R 1和R 2具有权利要求中所述的含义，R 3代表氢或C 1-4烷基，在脱水剂的存在下分离式R 3 OH的化合物。本发明还涉及式I化合物，其中R 2是卤素，以及含有表现出抗抑郁活性的式I化合物的组合物。

9. 发明授权

US4320127A Pyrido[3,2-e]-as-triazines 失效
标题翻译：吡啶并[3,2-e] -as-三嗪
公开(公告)号：US4320127A
公开(公告)日：1982-03-16
申请号：US152833
申请日：1980-05-23
申请人： Pal Benko , Andras Messmer , Gyorgy Hajos , Sandor Batori , Lujza Petocz , Iboly Kosoczky , Peter Gorog
发明人： Pal Benko , Andras Messmer , Gyorgy Hajos , Sandor Batori , Lujza Petocz , Iboly Kosoczky , Peter Gorog
IPC分类号： A61K31/53 , A61P25/00 , A61P25/04 , A61P25/20 , A61P29/00 , C07D471/04 , C07D471/14
CPC分类号： C07D471/04 , C07D471/14
摘要： The invention relates to new pyrido[3,2-e]-as-triazine derivatives of the formula I and pharmaceutically acceptable acid addition salts thereof, ##STR1## wherein R.sub.1 stands for a C.sub.1-20 alkyl-carbonyl group, halogen-C.sub.1-4 alkyl-carbonyl, benzoyl, phenyl-C.sub.1-4 alkyl-carbonyl, or pyridyl-carbonyl group;R.sub.2 is a hydrogen atom or a C.sub.1-4 alkyl-carbonyl group; or R.sub.1 and R.sub.2 form together with the adjacent nitrogen atoms a pyrazole-2,4-dione ring which carries a C.sub.1-6 alkyl substituent in position 3;R.sub.3 is a hydrogen atom, a C.sub.1-20 alkyl, phenyl, phenyl-C.sub.1-3 alkyl, furyl or pyridyl group or a phenyl group optionally substituted by one to three C.sub.1-4 alkoxy-groups.The compounds of the formula I are prepared by acylating the respective 1,2-un-substituted 1,2-dihydropyrido [3,2-e]-as-triazine derivatives. The new compounds exert valuable effects on the central nervous system and possess analgesic, antiphlogistic effects, and can be applied to advantage in therapy.
摘要翻译：本发明涉及式I的新的吡啶并[3,2-e] -as-三嗪衍生物及其药学上可接受的酸加成盐，其中R1代表C1-20烷基羰基，卤素C1 -4-烷基 - 羰基，苯甲酰基，苯基-C 1-4烷基 - 羰基或吡啶基 - 羰基; R2是氢原子或C1-4烷基 - 羰基; 或R 1和R 2与相邻的氮原子一起形成在3位上带有C1-6烷基取代基的吡唑-2,4-二酮环; R 3是氢原子，C 1-20烷基，苯基，苯基-C 1-3烷基，呋喃基或吡啶基或任选被一至三个C 1-4烷氧基取代的苯基。通过酰化相应的1,2-未取代的1,2-二氢吡啶并[3,2-e] -as-三嗪衍生物制备式I化合物。新化合物对中枢神经系统起重要作用，具有镇痛，消炎作用，可用于治疗。

10. 发明授权

US08420636B2 Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as CCR3 receptor ligands 失效
标题翻译：吡咯烷基 - 烷基 - 酰胺衍生物，它们的制备及其作为CCR3受体配体的治疗应用
公开(公告)号：US08420636B2
公开(公告)日：2013-04-16
申请号：US13014145
申请日：2011-01-26
申请人： Agnes Behr , Sandor Batori , Veronika Bartane Bodor , Zoltan Szlavik , Imre Bata , Katalin Urban-Szabo , Zoltan Kapui , Endre Mikus
发明人： Agnes Behr , Sandor Batori , Veronika Bartane Bodor , Zoltan Szlavik , Imre Bata , Katalin Urban-Szabo , Zoltan Kapui , Endre Mikus
IPC分类号： C07D513/04 , C07D207/08 , C07D417/14 , C07D405/12 , A61K31/4365 , A61K31/496 , A61K31/5377 , A61K31/4025 , A61K31/40
CPC分类号： C07D513/04 , C07D417/12
摘要： The present invention relates to pyrrolidinyl-alkyl-amide derivatives of formula (I) or (IA) wherein the variables are as defined herein, to their preparation and to their therapeutic use as CCR3 receptor ligands.
摘要翻译：本发明涉及式（I）或（IA）的吡咯烷基 - 烷基 - 酰胺衍生物，其中变量如本文所定义，其制备及其作为CCR3受体配体的治疗用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式